labetalol has been researched along with dobutamine in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (6.67) | 18.7374 |
1990's | 4 (26.67) | 18.2507 |
2000's | 3 (20.00) | 29.6817 |
2010's | 5 (33.33) | 24.3611 |
2020's | 2 (13.33) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Brockmöller, J; Dücker, C; Jensen, O | 1 |
Kashihara, M; Mizuguchi, M; Yokoyama, T | 1 |
Hicks, PR; Rankin, AP | 1 |
Bernard, R; Renard, M | 1 |
Downs, JB; Smith, RA; Thrush, D | 1 |
Hassan, E; Leslie, J; Martir-Herrero, ML | 1 |
Crooks, BN; Deshpande, SA; Hall, C; Milligan, DW; Platt, MP | 1 |
1 review(s) available for labetalol and dobutamine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for labetalol and dobutamine
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
Topics: Databases, Chemical; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Machine Learning; Octamer Transcription Factor-1; Organic Chemicals | 2021 |
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
Topics: Amyloid Neuropathies, Familial; Anthelmintics; Bithionol; Crystallography, X-Ray; Drug Repositioning; Humans; Prealbumin; Thermodynamics; Triclabendazole | 2021 |
Massive adrenaline doses in labetalol overdose.
Topics: Adult; Dobutamine; Dopamine; Drug Overdose; Epinephrine; Female; Humans; Isoproterenol; Labetalol | 1991 |
[Heart failure and acute myocardial infarct. Current treatment].
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Imidazoles; Labetalol; Myocardial Infarction; Phentolamine; Vasodilator Agents | 1983 |
Continuous thermodilution cardiac output: agreement with Fick and bolus thermodilution methods.
Topics: Adrenergic Agonists; Adrenergic Antagonists; Animals; Bias; Carbon Dioxide; Cardiac Catheterization; Cardiac Output; Catheterization, Swan-Ganz; Computers; Confidence Intervals; Dobutamine; Glucose; Hemodynamics; Infusions, Intravenous; Labetalol; Oxygen; Oxygen Consumption; Prospective Studies; Reproducibility of Results; Spirometry; Swine; Thermodilution; Thermometers | 1995 |
Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection.
Topics: Critical Care; Dobutamine; Drug Interactions; Drug Stability; Humans; Labetalol; Morphine; Nitroglycerin; Ranitidine | 1994 |
Adverse neonatal effects of maternal labetalol treatment.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Cardiomegaly; Dobutamine; Dopamine; Drug Therapy, Combination; Fatal Outcome; Female; Glucagon; Humans; Infant, Newborn; Labetalol; Norepinephrine; Pericardial Effusion; Pregnancy; Pregnancy Complications, Cardiovascular; Prenatal Exposure Delayed Effects | 1998 |